EUVIMEDEUVIMED entdecken
Crossref

Long-Residence Time Peptide Antagonist for the Vasopressin V 2 Receptor to Treat Autosomal Dominant Polycystic Kidney Disease

Xiaochun Xiong, Naiyuan Wang, Yixiao Zhang, Wenchao Zhao, Ningning Pang, Kequan Fu, Nan Zhou, Xueyan Zhou, Dong Guo iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c00217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Xiaochun Xiong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China. Hauptthemen laut MEDLINE: Polycystic Kidney, Autosomal Dominant. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China, Scientific Research Foundation for Talented Scholars in Xuzhou Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The dysregulated intracellular cAMP in the kidneys drives cystogenesis and progression in autosomal dominant polycystic kidney disease (ADPKD). Mounting evidence supports that vasopressin V2 receptor (V2R) antagonism effectively reduces cAMP levels, validating this receptor as a therapeutic target. Tolvaptan, an FDA-approved V2R antagonist, shows limitations in its clinical efficacy for ADPKD treatment. Therefore, the pursuit of better-in-class V2R antagonists with an improved efficacy remains pressing. Herein, we synthesized a set of peptide V2R antagonists. Peptide 33 exhibited a high binding affinity for the V2R (Ki = 6.1 ± 1.5 nM) and an extended residence time of 20 ± 1 min, 2-fold that of tolvaptan. This prolonged interaction translated into sustained suppression of cAMP production in washout experiments. Furthermore, peptide 33 exhibited improved efficacies over tolvaptan in both ex vivo and in vivo models of ADPKD, underscoring its potential as a promising lead compound for the treatment of ADPKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Kidney, Autosomal DominantHumansTolvaptanAntidiuretic Hormone Receptor AntagonistsKidneyVasopressinsReceptors, Vasopressin

Substanzen

TolvaptanAntidiuretic Hormone Receptor AntagonistsVasopressinsReceptors, Vasopressin

Autor:innen und Institutionen

  • Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, Jiangsu, China.

ORCID-Profile: Dong Guo

Förderung

  • Natural Science Foundation of Jiangsu Province
  • National Natural Science Foundation of China
  • Scientific Research Foundation for Talented Scholars in Xuzhou Medical University
  • Jiangsu Specially Appointed Professor program

Zitieren

APA

Xiong, X., Wang, N., Zhang, Y., Zhao, W., Pang, N., Fu, K., Zhou, N., Zhou, X., & Guo, D. (2024). Long-Residence Time Peptide Antagonist for the Vasopressin V 2 Receptor to Treat Autosomal Dominant Polycystic Kidney Disease. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00217

Vancouver

Xiong X, Wang N, Zhang Y, Zhao W, Pang N, Fu K, et al. Long-Residence Time Peptide Antagonist for the Vasopressin V 2 Receptor to Treat Autosomal Dominant Polycystic Kidney Disease. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00217

BibTeX
@article{Xiong2024,
  author = {Xiong, Xiaochun and Wang, Naiyuan and Zhang, Yixiao and Zhao, Wenchao and Pang, Ningning and Fu, Kequan and Zhou, Nan and Zhou, Xueyan and Guo, Dong},
  title = {Long-Residence Time Peptide Antagonist for the Vasopressin V 2 Receptor to Treat Autosomal Dominant Polycystic Kidney Disease},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c00217}
}
Kostenlos starten →